The estimated Net Worth of Heather M Bresch is at least $31.7 millió dollars as of 2 March 2020. Ms. Bresch owns over 143,709 units of Mylan NV stock worth over $4,802,534 and over the last 10 years she sold MYL stock worth over $8,385,000. In addition, she makes $18,509,300 as Chief Executive Officer és Executive Director at Mylan NV.
Sign up
Ms. Bresch MYL stock SEC Form 4 insiders trading
Heather has made over 12 trades of the Mylan NV stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 143,709 units of MYL stock worth $2,277,788 on 2 March 2020.
The largest trade she's ever made was exercising 378,071 units of Mylan NV stock on 10 June 2015 worth over $5,992,425. On average, Heather trades about 54,573 units every 102 days since 2015. As of 2 March 2020 she still owns at least 302,999 units of Mylan NV stock.
You can see the complete history of Ms. Bresch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Heather Bresch biography
Heather M. Bresch serves as Chief Executive Officer, Executive Director of the Company. Throughout her 28-year career with Mylan, Ms. Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Ms. Bresch served as the Company’s President, where she was responsible for its day-to-day operations. Before that, she served as Chief Operating Officer and Chief Integration Officer, leading the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business – which more than doubled Mylan’s size and transformed it from a purely U.S. company to a global one. As CEO, Ms. Bresch has been leading the latest chapter of Mylan’s growth and performance, pursuing a strategy that has produced a sustainable organization that is making great strides in its mission of delivering better health for a better world by providing seven billion people access to high quality medicine. In continuing to execute on this strategy, Ms. Bresch is focused on further diversifying the Company in terms of products, markets and channels, a process proven to expand access and generate durable cash flows that can be reinvested to further differentiate Mylan and position it to support the transformation of outdated healthcare systems.
What is the salary of Heather Bresch?
As the Chief Executive Officer és Executive Director of Mylan NV, the total compensation of Heather Bresch at Mylan NV is $18,509,300. There are no executives at Mylan NV getting paid more.
How old is Heather Bresch?
Heather Bresch is 50, she's been the Chief Executive Officer és Executive Director of Mylan NV since 2016. There are 12 older and no younger executives at Mylan NV. The oldest executive at Mylan NV is Robert Cindrich, 76, who is the Non-Executive Independent Director.
What's Heather Bresch's mailing address?
Heather's mailing address filed with the SEC is BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, , HATFIELD, HERTFORDSHIRE, X0, AL10 9UL.
Insiders trading at Mylan NV
Over the last 10 years, insiders at Mylan NV have traded over $1,861,785,794 worth of Mylan NV stock and bought 202,008 units worth $5,767,632 . The most active insiders traders include Laboratories Abbott Product..., Daniel Martin Jr Gallagher és Robert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of $5,605,891. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth $149,624.
What does Mylan NV do?
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
What does Mylan NV's logo look like?
Complete history of Ms. Bresch stock trades at Mylan NV
Mylan NV executives and stock owners
Mylan NV executives and other stock owners filed with the SEC include:
-
Heather Bresch,
Chief Executive Officer, Executive Director -
Rajiv Malik,
President, Executive Director -
Robert Coury,
Executive Chairman of the Board -
Mark Parrish,
Lead Independent Non-Executive Vice Chairman of the Board -
JoEllen Dillon,
Non-Executive Independent Director -
Neil Dimick,
Non-Executive Independent Director -
Melina Higgins,
Non-Executive Independent Director -
Sjoerd Vollebregt,
Non-Executive Independent Director -
Robert Cindrich,
Non-Executive Independent Director -
Harry Korman,
Non-Executive Independent Director -
Randall Vanderveen,
Non-Executive Independent Director -
Pauline van der Meer Mohr,
Non-Executive Independent Director -
Richard Mark,
Non-Executive Independent Director -
Melissa Trombetta,
Head of Global Investor Relations -
Joseph C Md Maroon,
Director -
Rodney L Piatt,
Director -
Paul Campbell,
See Remarks -
Laboratories Abbott Product...,
-
Kenneth Scott Parks,
Chief Financial Officer -
Wendy Cameron,
Director -
Douglas J Leech,
Director -
Daniel Martin Jr Gallagher,
Chief Legal Officer -
Anthony Mauro,
Chief Commercial Officer -
John D Sheehan,
EVP and CFO -
Laboratories Abbott Establi...,
-
Laboratories Laboratoires F...,